|
表中引用指南和文献（按照字母顺序排列）： [1] Gibbons et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies andvarying degrees of renal dysfunction: a study by the National CancerInstitute Organ Dysfunction Working Group. [2] Iddawela et al. Safety and efficacy of vemurafenib in end stage renal failure. [3]Imai et al. Successful afatinib treatment of advancednon-small-cell lung cancer patients undergoing hemodialysis. [4]Miller et al. Phase I and pharmacokinetic study ofsorafenib in patients with hepatic or renal dysfunction: CALGB 60301. [5]Masini et al. Use of tyrosine kinase inhibitors inpatients with metastatic kidney cancer receiving haemodialysis: aretrospective Italian survey. [6]Park et al. Pharmacokinetics of dabrafenib in a patientwith metastatic melanoma undergoing haemodialysis. [7]Weil et al. Pharmacokinetics of vandetanib in subjectswith renal or hepatic impairment. 表中缩写： CCO:加拿大安大略癌症治疗中心 USPI：美国处方信息 NMPA：国家药品监督管理局 ALK：间变性淋巴瘤激酶 BCL-2：B淋巴细胞瘤-2基因 BTK：布鲁顿酪氨酸激酶 EGFR：表皮生长因子 HER2：人表皮生长因子受体2 MEK：丝裂原活化细胞外激酶 mTOR：西罗莫司机能靶点 PARP：聚腺苷二磷酸核糖聚合酶 TLS：肿瘤溶解综合征 VEGF：血管内皮生长因子 |
|
|
